PUBLISHER: The Business Research Company | PRODUCT CODE: 1751143
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751143
Tourette syndrome (TS) is a neurological disorder characterized by involuntary, repetitive movements and vocalizations known as tics. Typically beginning in childhood, TS can vary in severity and is influenced by both genetic and environmental factors. Symptoms often worsen during times of stress or excitement. Treatment options, including behavioral therapy and medication, can help manage and reduce the frequency of tics.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of tics in Tourette syndrome are motor tics and vocal tics. Motor tics involve sudden, involuntary body movements, such as blinking, head jerking, or shoulder shrugging. TS can be diagnosed through blood tests, imaging, and other diagnostic methods. Treatment options include medications, behavioral therapy, neuromodulation therapies, complementary and alternative medicine, among others. The severity of TS can be mild, moderate, or severe, and it is addressed by individuals with Tourette syndrome, healthcare professionals, educational institutions, non-profit organizations, and research institutions.
The tourette syndrome market research report is one of a series of new reports from The Business Research Company that provides tourette syndrome market statistics, including tourette syndrome industry global market size, regional shares, competitors with a tourette syndrome market share, detailed tourette syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the tourette syndrome industry. This tourette syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tourette syndrome market size has grown rapidly in recent years. It will grow from $1.95 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed during the historical period can be linked to a greater awareness of neurological disorders, a rise in the prevalence of tic disorders, expanding research on genetic factors, increased funding for rare disease research, and a growing demand for personalized medicine.
The tourette syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.20 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth projected during the forecast period can be attributed to expanding public health initiatives for neurological disorders, a rising prevalence of co-occurring psychiatric conditions, an increase in clinical trials for new treatment options, a growing demand for alternative and complementary therapies, and a rise in the use of natural and herbal remedies. Key trends during this period include the development of gene-based therapies, advancements in deep brain stimulation technology, the creation of machine learning models for symptom prediction, the introduction of wearable neurofeedback devices, and the integration of virtual reality into behavioral therapy.
Government initiatives aimed at addressing neurological disorders are expected to significantly contribute to the growth of the Tourette syndrome market. These initiatives involve programs, policies, or actions carried out by authorities to meet public needs, promote progress, or improve societal well-being. Such government efforts drive advancements in Tourette syndrome treatment by increasing funding for research and therapeutic programs, leading to better diagnostic tools, enhanced treatment options, and increased public awareness, ultimately improving patient care and support. For example, in February 2025, the Department of Health and Social Care, a UK-based ministerial department, reported that the Medical Research Council (MRC) established two Centres of Research Excellence (CoRE) in December 2024, each dedicated to gene therapy research with investments of up to $65 million (£50 million) over 14 years. One of these centers, focused on therapeutic genomics, aims to make significant strides in treating rare genetic disorders by developing scalable processes for adapting successful genetic therapies to new conditions, thus facilitating the creation of personalized treatments. As a result, these growing government initiatives are driving the advancement of the Tourette syndrome market.
Leading companies in the Tourette syndrome market are prioritizing the development of technologically advanced products, such as wearable devices, to improve symptom monitoring, patient management, and treatment outcomes. Wearable devices are smart electronic gadgets worn on the body that track and analyze health or activity data in real time. For example, in May 2022, Neurotherapeutics Ltd., a UK-based health tech company, initiated a clinical trial for a wearable device designed to manage Tourette syndrome. This device works by delivering targeted electrical stimulation to the median nerve at the wrist, modulating brain oscillations related to tic suppression, thus reducing their frequency and intensity. Non-invasive and user-friendly, the device can be easily integrated into daily life, providing individuals with a convenient and discreet treatment option that can be used at home, thanks to its wristwatch-like design.
In February 2025, Relmada Therapeutics Inc., a US-based biotechnology firm, acquired Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB for an undisclosed amount. This acquisition aligns with Relmada's goal of addressing unmet needs in treating central nervous system (CNS) disorders. Sepranolone has shown promising results in Phase 2a trials, demonstrating significant reductions in tics and improvements in quality of life, along with strong safety data. Asarina Pharma AB, based in Sweden, is a provider of treatments for Tourette syndrome.
Major players in the tourette syndrome market are AstraZeneca PLC, F Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd, Otsuka Holdings Co Ltd, Biogen Inc, Mitsubishi Tanabe Pharma Corporation, Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Neurocrine Biosciences Inc.
North America was the largest region in the tourette syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tourette syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tourette syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tourette syndrome market consists of sales of sensory stimulation devices, neurofeedback devices, speech and communication aids, mental health support apps. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tourette Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on tourette syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for tourette syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tourette syndrome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.